SARS–CoV‐2 infection and COVID‐19 outcomes in rheumatic diseases: a systematic literature review and meta‐analysis
Objective The relative risk of SARS–CoV‐2 infection and COVID‐19 disease severity among
people with rheumatic and musculoskeletal diseases (RMDs) compared to those without …
people with rheumatic and musculoskeletal diseases (RMDs) compared to those without …
Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data
Objectives The impact of rheumatic diseases on COVID-19 infection remains poorly
investigated. Here we performed a systematic review and meta-analysis to evaluate the …
investigated. Here we performed a systematic review and meta-analysis to evaluate the …
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported …
A Strangfeld, M Schäfer, MA Gianfrancesco… - Annals of the …, 2021 - ard.bmj.com
Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …
Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients
TW Kragstrup, HS Singh, I Grundberg, ALL Nielsen… - PloS one, 2021 - journals.plos.org
Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin
converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the …
converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the …
Understanding the co-epidemic of obesity and COVID-19: current evidence, comparison with previous epidemics, mechanisms, and preventive and therapeutic …
M Dalamaga, GS Christodoulatos, I Karampela… - Current obesity …, 2021 - Springer
Purpose of Review A growing body of evidence suggests that obesity and increased visceral
adiposity are strongly and independently linked to adverse outcomes and death due to …
adiposity are strongly and independently linked to adverse outcomes and death due to …
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis
F Barkas, S Filippas-Ntekouan, M Kosmidou… - …, 2021 - academic.oup.com
Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …
major complications of coronavirus disease 2019 (COVID-19) associated with increased …
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
K Dahms, A Mikolajewska, K Ansems… - European journal of …, 2023 - Springer
Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …
Deciphering SARS-CoV-2 virologic and immunologic features
G Lebeau, D Vagner, E Frumence, F Ah-Pine… - International journal of …, 2020 - mdpi.com
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated
pathology, COVID-19, have been of particular concerns these last months due to the …
pathology, COVID-19, have been of particular concerns these last months due to the …
Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity
ML Saiz, ML De Diego, D López-García… - Clinical …, 2021 - Springer
Background SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) and neuropilin-
1 (NRP1) receptors for entry into cells, and the serine protease TMPRSS2 for S protein …
1 (NRP1) receptors for entry into cells, and the serine protease TMPRSS2 for S protein …
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes
There is concern that people with rheumatic disease, often treated with immunosuppressive
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …